BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 28332360)

  • 21. Emergence of entecavir-resistant mutations in nucleos(t)ide-naive Japanese patients infected with hepatitis B virus: virological breakthrough is also dependent on adherence to medication.
    Kamezaki H; Kanda T; Wu S; Nakamoto S; Arai M; Maruyama H; Fujiwara K; Imazeki F; Yokosuka O
    Scand J Gastroenterol; 2011 Sep; 46(9):1111-7. PubMed ID: 21623676
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antiviral efficacy of combination therapy with entecavir and adefovir for entecavir/lamivudine-resistant hepatitis B virus with or without adefovir resistance.
    Yang HJ; Lee JH; Kim YJ; Yoon JH; Lee HS
    J Med Virol; 2012 Mar; 84(3):424-30. PubMed ID: 22246827
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tenofovir versus tenofovir plus entecavir for chronic hepatitis B with lamivudine resistance and entecavir resistance.
    Lee S; Ahn SH; Jung KS; Kim DY; Kim BK; Kim SU; Baatarkhuu O; Ku HJ; Han K; Park JY
    J Viral Hepat; 2017 Feb; 24(2):141-147. PubMed ID: 27766731
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized controlled trial of sequential pegylated interferon-α and telbivudine or vice versa for 48 weeks in hepatitis B e antigen-negative chronic hepatitis B.
    Piccolo P; Lenci I; di Paolo D; Demelia L; Sorbello O; Nosotti L; Angelico M
    Antivir Ther; 2013; 18(1):57-64. PubMed ID: 22872648
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of the antiviral effects of different nucleos(t)ide analogues in chinese patients with chronic hepatitis B: a head-to-head study.
    Yu S; Zhou Q; Zhao XM; Yuan M; Wang CT; Cheng XG; Zhang ZH; Li X
    Saudi J Gastroenterol; 2014; 20(6):350-5. PubMed ID: 25434315
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B.
    Lok AS; Trinh H; Carosi G; Akarca US; Gadano A; Habersetzer F; Sievert W; Wong D; Lovegren M; Cohen D; Llamoso C
    Gastroenterology; 2012 Sep; 143(3):619-628.e1. PubMed ID: 22643350
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy.
    Li N; Xu JH; Yu M; Wang S; Si CW; Yu YY
    World J Gastroenterol; 2015 Nov; 21(43):12421-9. PubMed ID: 26604649
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antiviral efficacy of entecavir for hepatitis B virus rtA181V/T mutants.
    Li P; Geng J; Li W; Xu X; Zhang X; Zheng W; Yu Y; Yang Z; Wang M
    Virol J; 2017 Apr; 14(1):68. PubMed ID: 28376852
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term virological outcome in chronic hepatitis B patients with a partial virological response to entecavir.
    Jo YJ; Kim KA; Lee JS; Kim NH; Bae WK; Song TJ; Kim JW
    Korean J Intern Med; 2015 Mar; 30(2):170-6. PubMed ID: 25750558
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of 208-week sequential therapy with telbivudine and entecavir in HBeAg-positive chronic hepatitis B patients with suboptimal responses to 24 weeks of Peg-IFNα-2a therapy: An open-labelled, randomized, controlled, "real-life" trial.
    Luo XD; Chen XF; Zhou Y; Chen XP
    J Viral Hepat; 2017 Nov; 24 Suppl 1():36-42. PubMed ID: 29082651
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Simultaneous emergence of entecavir resistance mutations in a nucleoside-naive chronic hepatitis B patient.
    Lee HW; Kim HJ; Hong SP; Cha BK; Chang HY; Choi CH; Do JH; Kim JG; Chang SK
    Intervirology; 2012; 55(5):380-4. PubMed ID: 22538265
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of lamivudine or entecavir against virological rebound after achieving HBV DNA negativity in chronic hepatitis B patients.
    Miyauchi T; Kanda T; Shinozaki M; Kamezaki H; Wu S; Nakamoto S; Kato K; Arai M; Mikami S; Sugiura N; Kimura M; Goto N; Imazeki F; Yokosuka O
    Int J Med Sci; 2013; 10(6):647-52. PubMed ID: 23569428
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dynamics of hepatitis B virus resistance substitutions correlates with virological response in lamivudine-refractory patients with entecavir rescue monotherapy.
    Zhang Y; He S; Li QL; Guo JJ
    Virus Res; 2013 Nov; 177(2):156-62. PubMed ID: 23968804
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy.
    Kim HJ; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI
    J Gastroenterol Hepatol; 2010 Aug; 25(8):1374-80. PubMed ID: 20659226
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adefovir and lamivudine combination therapy in patients with entecavir-resistant chronic hepatitis B: antiviral responses and evolution of mutations.
    Yim HJ; Lee HJ; Suh SJ; Seo YS; Kim CW; Lee CD; Park SH; Lee MS; Park CK; Chae HB; Kim MY; Baik SK; Kim YS; Kim JH; Lee JI; Lee JW; Hong SP; Um SH
    Intervirology; 2014; 57(5):239-47. PubMed ID: 24993731
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lamivudine switch therapy in chronic hepatitis B patients achieving undetectable hepatitis B virus DNA after 3 years of entecavir therapy: A prospective, open-label, multicenter study.
    Yeh ML; Huang CI; Hsieh MY; Huang CF; Hsieh MH; Huang JF; Dai CY; Lin ZY; Chen SC; Yu ML; Chuang WL
    Kaohsiung J Med Sci; 2016 Nov; 32(11):559-566. PubMed ID: 27847098
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy.
    Park JG; Park SY
    Clin Mol Hepatol; 2015 Sep; 21(3):242-8. PubMed ID: 26523269
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of Lamivudine, Telbivudine, Adefovir Dipivoxil and Entecavir on decompensated hepatitis B virus-related cirrhosis.
    Wang GL; Liu Y; Qiu P; Zhou SF; Xu LF; Wen P; Wen JB; Xiao XZ
    Eur Rev Med Pharmacol Sci; 2016 Mar; 20(5):866-72. PubMed ID: 27010143
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir.
    Leung N; Peng CY; Hann HW; Sollano J; Lao-Tan J; Hsu CW; Lesmana L; Yuen MF; Jeffers L; Sherman M; Min A; Mencarini K; Diva U; Cross A; Wilber R; Lopez-Talavera J
    Hepatology; 2009 Jan; 49(1):72-9. PubMed ID: 19065670
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone.
    Shim JH; Suh DJ; Kim KM; Lim YS; Lee HC; Chung YH; Lee YS
    Hepatology; 2009 Oct; 50(4):1064-71. PubMed ID: 19637288
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.